Forecasting of the efficiency of monoclonal therapy in the treatment of CoViD-19 induced by the Omicron variant of SARS-CoV2

Abstract

On November 26, 2021, the World Health Organization (WHO) announced a new variant of concern of SARS-CoV2 called Omicron. This variant has biological–functional characteristics such as to make it much faster in the infectious process so as to show an even more intense spread. Although many data are currently incomplete, it is possible to identify, based on the viral biochemical characteristics, a possible therapy consisting of a monoclonal antibody called Sotrovimab. The model proposed here is based on the mathematical analysis of the dynamics of action of this monoclonal antibody and two cell populations: the immune memory cells and the infected cells. Indeed, a delay exists during the physiological immune response and the response induced by administration of Sotrovimab. This manuscript presents that delay in a novel manner. The model is developed with the aid of information based on the chemical kinetics. The machine learning tools have been used to satisfy the criteria designed by the dynamical analysis. Regression learner tools of Python are used as the reverse engineering tools for the understanding of the balance in the mathematical model, maintained by the parameters and their corresponding intervals and thresholds set by the dynamical analysis.